Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | MLNR | O43193 | 3/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.38 |
| ▸ | CYP2A13 | Q16696 | 2/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1997561 | 0.89 | METAP2 (0.43) | METAP2BRD4DHODHHRH3BCL2 | |
| SCHEMBL1998382 | 0.88 | METAP2 (0.42) | METAP2BRD4DHODHBACE1HRH3 | |
| SCHEMBL2000635 | 0.87 | METAP2 (0.42) | METAP2BRD4DHODHHRH3BCL2 | |
| SCHEMBL1998644 | 0.85 | METAP2 (0.43) | METAP2BRD4DHODHHRH3BCL2 | |
| SCHEMBL1998519 | 0.83 | CYP2A13 (0.42) | METAP2BRD4DHODHHRH3BCL2 | |
| SCHEMBL2001280 | 0.83 | CYP2A13 (0.42) | METAP2BRD4DHODHHRH3BCL2 | |
| SCHEMBL1998347 | 0.83 | METAP2 (0.41) | METAP2BRD4DHODHBACE1HRH3 | |
| SCHEMBL1996183 | 0.83 | HRH3 (0.40) | METAP2DHODHHRH3BCL2BCL2L1 | |
| SCHEMBL1996290 | 0.82 | DHODH (0.42) | METAP2BRD4DHODHHRH3BCL2 | |
| SCHEMBL2001274 | 0.81 | HRH3 (0.38) | METAP2BRD4DHODHHRH3BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960560-B2 | 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione | N.V. ORGANON (NL) | 2011-06-14 | — | — | US | claimed |
| US-20100144723-A1 | 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE | N. V. ORGANON | 2010-06-10 | — | — | US | claimed |
| EP-2373627-A1 | 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS | N.V. Organon (NL) | 2011-10-12 | — | — | EP | disclosed |
| US-7960560-B2 | 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione | N.V. ORGANON (NL) | 2011-06-14 | — | — | US | disclosed |
| US-20100144723-A1 | 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE | N. V. ORGANON | 2010-06-10 | — | — | US | disclosed |
| WO-2010063721-A1 | 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS | N.V. ORGANON (NL) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144723-A1 | 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE | OPRM1, OR10J3, OPRD1 | METAP2 3694/4885MLNR 1516/4885BRD4 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.